Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Applied Clear All

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Article
    Jin Y, Wu J, Song X, Song Q, Cully BL, Messmer-Blust A, Xu M, Foo SY, Rosenzweig A, Li J.
    J Biol Chem. 2011 Jun 24;286(25):22699-705.
    The amount of available hypoxia-inducible factor (HIF)-1α has been considered to be largely a consequence of post-translational modification by multiple ubiquitin-proteasome pathways. However, the role of transcriptional regulation of HIF-1α is less certain, and the mechanisms of transcriptional regulation of HIF-1α require further investigation. Here we report that related transcriptional enhancer factor-1 (RTEF-1), a member of the TEF transcriptional factor family, transcriptionally regulates the HIF-1α gene under normoxic and hypoxic conditions. The expression of HIF-1α mRNA was decreased in endothelial cells in which RTEF-1 was knocked down with siRNA. Sequential deletional analysis of the HIF-1α promoter revealed that the MCAT-like element in the HIF-1α promoter was essential for HIF-1α transcription. Binding of RTEF-1 to the MCAT-like element was confirmed by ChIP. Treatment of endothelial cells with a HIF-1 inhibitor resulted in retardation of RTEF-1-induced proliferation and tube formation. Moreover, increased HIF-1α expression was observed in transgenic mice expressing RTEF-1 under the VE-cadherin promoter (VE-Cad/RTEF-1). VE-Cad/RTEF-1 mice subjected to hindlimb ischemia demonstrated increased levels of HIF-1α, accelerated recovery of blood flow, and increased capillary density compared with littermate controls. These results identify RTEF-1 as a regulator of HIF-1α transcription, which results in up-regulation of HIF-1α and acceleration of recovery from ischemia.
    Digital Access Access Options
  • Article
    Li Y, Brodsky B, Baum J.
    J Biol Chem. 2007 Aug 03;282(31):22699-706.
    Little is known about the structural consequences of the more than 20 breaks in the (Gly-X-Y)(n) repeating sequence found in the long triple helix domain of basement membrane type IV collagen. NMR triple resonance studies of doubly labeled residues within a set of collagen model peptides provide distance and dihedral angle restraints that allow determination of model structures of both a standard triple helix and of a triple helix with a break in solution. Although the standard triple helix cannot continue when Gly is not every third residue, the NMR data support rod-like molecules that have standard triple-helical structures on both sides of a well defined and highly localized perturbation. The GAAVM break region may be described as a "pseudo triple helix," because it preserves the standard one-residue stagger of the triple helix but introduces hydrophobic interactions at the position normally occupied by the much smaller and hydrogen-bonded Gly residue of the repeating (Gly-X-Y)(n) sequence. This structure provides a rationale for the consensus presence of hydrophobic residues in breaks of similar length and defines a novel variant of a triple helix that could be involved in recognition.
    Digital Access Access Options
  • Article
    Smerdel-Ramoya A, Zanotti S, Deregowski V, Canalis E.
    J Biol Chem. 2008 Aug 15;283(33):22690-9.
    Connective tissue growth factor (CTGF), a member of the CCN family of proteins, is expressed by osteoblasts, but its function in cells of the osteoblastic lineage has not been established. We investigated the effects of CTGF overexpression by transducing murine ST-2 stromal cells with a retroviral vector, where CTGF is under the control of the cytomegalovirus promoter. Overexpression of CTGF in ST-2 cells increased alkaline phosphatase activity, osteocalcin and alkaline phosphatase mRNA levels, and mineralized nodule formation. CTGF overexpression decreased the effect of bone morphogenetic protein-2 on Smad 1/5/8 phosphorylation and of Wnt 3 on cytosolic beta-catenin, indicating that the stimulatory effect on osteoblastogenesis was unrelated to BMP and Wnt signaling. CTGF overexpression suppressed Notch signaling and induced the transcription of hairy and E (spl)-1 (HES)-1, by Notch-independent mechanisms. CTGF induced nuclear factor of activated T cells (NFAT) transactivation by a calcineurin-dependent mechanism. Down-regulation of CTGF enhanced Notch signaling and decreased HES-1 transcription and NFAT transactivation. Similar effects were observed following forced CTGF overexpression, the addition of CTGF protein, or the transduction of ST-2 cells with a retroviral vector expressing HES-1. In conclusion, CTGF enhances osteoblastogenesis, possibly by inhibiting Notch signaling and inducing HES-1 transcription and NFAT transactivation.
    Digital Access Access Options
  • Article
    Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, Cogdill AP, Mancuso JJ, Wargo JA, Pe'er D, Allison JP.
    Proc Natl Acad Sci U S A. 2019 11 05;116(45):22699-22709.
    Immune checkpoint blockade therapy targets T cell-negative costimulatory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1). Combination anti-CTLA-4 and anti-PD-1 blockade therapy has enhanced efficacy, but it remains unclear through what mechanisms such effects are mediated. A critical question is whether combination therapy targets and modulates the same T cell populations as monotherapies. Using a mass cytometry-based systems approach, we comprehensively profiled the response of T cell populations to monotherapy and combination anti-CTLA-4 plus anti-PD-1 therapy in syngeneic murine tumors and clinical samples. Most effects of monotherapies were additive in the context of combination therapy; however, multiple combination therapy-specific effects were observed. Highly phenotypically exhausted cluster of differentiation 8 (CD8) T cells expand in frequency following anti-PD-1 monotherapy but not combination therapy, while activated terminally differentiated effector CD8 T cells expand only following combination therapy. Combination therapy also led to further increased frequency of T helper type 1 (Th1)-like CD4 effector T cells even though anti-PD-1 monotherapy is not sufficient to do so. Mass cytometry analyses of peripheral blood from melanoma patients treated with immune checkpoint blockade therapies similarly revealed mostly additive effects on the frequencies of T cell subsets along with unique modulation of terminally differentiated effector CD8 T cells by combination ipilimumab plus nivolumab therapy. Together, these findings indicate that dual blockade of CTLA-4 and PD-1 therapy is sufficient to induce unique cellular responses compared with either monotherapy.
    Digital Access Access Options